{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-003121","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.062808+00:00","generated_at":"2026-05-16T10:38:40.085101+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FDA approves ZYCUBO for Menkes disease; Cyprium gets PRV, up to $129M milestones","bullets":["FDA approved ZYCUBO (copper histidinate) as first and only U.S. treatment for Menkes disease in pediatric patients.","Rare Pediatric Disease PRV issued at approval and will be transferred to Cyprium, a majority-owned Fortress subsidiary.","Cyprium eligible for tiered royalties on net sales and up to $129M in aggregate development and sales milestones from Sentynl.","Early ZYCUBO treatment showed median overall survival of 177.1 months vs 17.6 months in external control (≈80% risk reduction).","Fortress notes three FDA approvals in 15 months (Emrosi, UNLOXCYT, ZYCUBO) and recent $28M upfront from Checkpoint sale to Sun Pharma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-003121","json":"https://secwatch.observer/filing/0001104659-26-003121.json","markdown":"https://secwatch.observer/filing/0001104659-26-003121.md","text":"https://secwatch.observer/filing/0001104659-26-003121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000110465926003121/0001104659-26-003121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000110465926003121/fbio-20260113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:38:40.085101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}